Article

Evaluation of Orally Administered Salbutamol in the Relief of Bronchospasm in Bronchial Asthma

Authors: J. S. GULERIA MD, G. K. BATRA MD, S. P. GUPTA MD, J. N. PANDE MD

Abstract

AbstractA single oral dose of 2 mg salbutamol produces significantly greater bronchodilatation than a placebo in patients with bronchial asthma. The degree of bronchodilatation is comparable to tha produced by 10 mg isoprenaline given sublingually. The effect of salbutamol starts within half an hour and continues up to six hours. Salbutamol appears to have a selective stimulant action so that the cardiovascular side effects are minimal. Unlike other conventional bronchodilators, it does not aggravate exiting hypoxemia. Salbutamol, therefore, appears to be a superior bronchodilator when compared to other sympathomimetic drugs.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References